Milestones

• On December 15, 2015, Beijing tricision Biotechnology Co., Ltd. was established.

2016

• In January 2016, three exploratory clinical trials including primary glioma cell immunotherapy, recurrent glioma cell immunotherapy, and solid tumor brain metastasis cell immunotherapy were conducted in cooperation with Guangdong Sanjiu Brain Hospital.
• In January 2016, the first patient with lung cancer brain metastasis was enrolled.
• In February 2016, the first patient with primary brain glioma was enrolled.

2017

• In September 2017, tricision was selected for the "Zhuhai Introduces High-level Health Discipline Team" project to conduct clinical exploration and research on highly individualized liver cancer immunotherapy.
• In November 2017, we cooperated with the First Affiliated Hospital of China Medical University to conduct cooperative research on national "13th Five-Year Plan" major special projects.

2018

• On August 30, 2018, tricision Biotechnology (Zhuhai) Co., Ltd. was established.
• In September 2018, we cooperated with Zhuhai People's Hospital to conduct exploratory clinical trial research on liver cancer cell immunotherapy.
• In December 2018, we obtained the exclusive license of the modified antigen patent technology from TriVac.

2020

• In January 2020, we undertook the special project of "Novel Coronavirus Infection Prevention and Control" emergency scientific and technological research in Zhuhai.
• On February 20, 2020, tricision Inc. published a paper “Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients” on Cancer Immunol Immunother, which is an article that provides a phase summary of our tumor-associated antigens (TAAs)-based personalized dendritic cell vaccine in solid tumor patients.
• On March 27, 2020, tricision Inc. published a paper “Enhanced Human T Lymphocyte Antigen Priming by Cytokine-Matured Dendritic Cells Overexpressing Bcl-2 and IL-12” on Front Cell Dev Biol, which suggested that DC matured by the four-cytokine cocktail combined with exogenous Bcl-2 and IL-12p70 gene expression represents a promising approach for clinical applications in cancer immunotherapy.
• On July 17, 2020, tricision Inc. published a paper “Preventing Mortality in COVID-19 Patients: Which Cytokine to Target in a Raging Storm?” on Front Cell Dev Biol, which is a review discussing critical factors in determining appropriate inflammatory cytokine/chemokine targets, timing, and combination of treatments to prevent COVID-19 mortality.
• In July 2020, we undertook the key special topic of infectious diseases in Beijing's "Science and Technology Helps Economy 2020".
• In September 2020, tricision was awarded the "Top 100 Makers Beijing 2020" by the Beijing Municipal Bureau of Economy and Information Technology, Beijing Municipal Bureau of Finance, and Zhongguancun Science City Management Committee.
• In August 2020, the GMP-grade mRNA nanovaccine production line was put into use in Beijing.
• In December 2020, GMP-grade nucleic acid nanolab and production line were put into use in Zhuhai.
• On December 1, 2020, tricision Inc. published a paper “Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?” on Sci China Life Sci, which is a review that summarizes recent research progress of antibody response and therapy in COVID-19 patients and discusses the implications of these findings in vaccine development.

2021

• In January 2021, tricision was selected for the database of high-growth innovative enterprises (unicorn enterprises) in Zhuhai.
• In January 2021, we undertook the special project of "Cultivation of pharmaceutical Innovative varieties and platforms" in Beijing.
• In January 2021, tricision Inc. published a paper “Targeting Neoantigens in Hepatocellular Carcinoma for Immunotherapy: A Futile Strategy?” on Hepatology. The paper discussed the limits of using neoantigens as targets in hepatocellular carcinoma (HCC) immunotherapy and suggested alternative strategies to overcome these limits.
• In February 2021, tricision Inc. published a paper “Targeting Tumor-Associated Antigens in Hepatocellular Carcinoma for Immunotherapy: Past Pitfalls and Future Strategies” on Hepatology, which proposed a three-pronged cancer vaccine platform that induces simultaneous activation of the three important cellular components of adaptive immunity: B lymphocytes, CD4+ T cells, and CD8+ T cells.
• In May 2021, the company independently established a tertiary antigen bank for malignant tumors and infectious diseases in line with the standards of Chinese Pharmacopoeia.
• In August 2021, mRNA-LNP products reached grade g for the first time.
• In October 2021, it won the "Star Glory List" 2021 Top 50 Most Innovative Chinese Biopharmaceutical Enterprises.
• In October 2021, tricision was recognized as "Zhongguancun High-tech Enterprise".
• On December 24, 2021, a global strategic cooperation agreement was signed with Thermo Fisher Scientific.

2022

• In January 2022, tricision was recognized as a "National high-tech Enterprise".
• In February 2022, a glioblastoma patient treated with PERCELLVAC had a survival of 60 months.
• In February 2022, tricision fully deployed the patent layout of the novel coronavirus product pipeline.
• On February 22, 2022, tricision and Mingdu Zhiyun Technology Co., Ltd signed a strategic cooperation agreement to jointly promote the transformation of medical information, digitalization and intelligent ecology.
• On June 3, 2022, tricision Inc. published a paper “Clinically approved combination immunotherapy: Current status, limitations, and future perspective” on Curr Res Immunol. The paper provided a perspective analysis of the limitations of combination immunotherapies and potential approaches to overcome the limitations.
• On June 15, 2022, tricision won the "2022 Future Medical Top 100 · Value Field List".
• On July 15, 2022, tricision Biotechnology (Zhuhai) Co., Ltd. was recognized as "Zhuhai Key Enterprise of Intellectual Property Protection".
• On August 3, 2022, tricision Biotechnology (Zhuhai) Co., Ltd. was successfully selected into the "List of Innovation-driven Enterprises in Zhuhai Golden Bay Area".
• On August 5, 2022, the "International Personalized Immune Cell Therapy Summit Forum" co-organized by tricision was successfully held in Xi 'an, and some stage clinical data were officially published and disclosed.
• On August 13, 2022, tricision won the third prize in the final of the 2022 "Digital Intelligence New Industry" Life Health Innovation and Entrepreneurship Competition.
• On August 31, 2022, Beijing tricision Biotechnology Co., Ltd. was successfully selected as the "Beijing Intellectual Property Pilot Unit".
• On September 2, 2022, tricision signed a strategic cooperation agreement with Yixing Environmental Science and Technology Industrial Park.
• In October 2022, Beijing tricision Biotechnology Co., Ltd. was successfully recognized as a "specialized and special new small and medium-sized enterprise".
• On November 22, 2022, tricision Biotechnology (Zhuhai) Co., Ltd. won the honorary title of "Excellent Enterprise" in the 11th China Innovation and Entrepreneurship Competition Biomedicine National Competition.

2023

• On January 10, 2023, the mRNA-DC vaccine targeting Survivin DC cell injection developed by us for the treatment of glioblastoma received clinical trial approval (approval number: 2023LP00065).
• On February 20, 2023, the biotechnology achievements of tricision won the 2022 "Science and Technology China" pilot technology list.
• In February 2023, tricision Inc. published a paper “A highly efficient needle-free-injection delivery system for mRNA-LNP vaccination against SARS-CoV-2” on Nano Today, which introduced a vaccine-delivery system with a combination of a needle-free injection (NFI) device and a SARS-CoV-2-Spike-specific mRNA-Lipid Nanoparticle (LNP) vaccine.
• In March 2023, tricision won the Excellence Award in the finals of the 2022 National Disruptive Technology Innovation Competition.
• On April 26, 2023, Thermo Field Scientific and tricision signed a memorandum of strategic cooperation.
• In June 2023, tricision Inc. published a paper “Combination immunotherapy of glioblastoma with dendritic cell cancer vaccines, anti-PD-1 and poly I:C” on J Pharm Anal, which reported a Glioblastoma (GBM) case with integrated combination immunotherapy consisting of DC-based cancer vaccines, anti-PD-1 and poly I:C treatment.
• On November 7, 2023, Beijing tricision Technology Co., Ltd. won the title of "National High-tech Enterprise".
• On September 4, 2024, tricision Inc. published a paper “Sintilimab (anti-PD-1 antibody) combined with high-dose methotrexate, temozolomide, and rituximab (anti-CD20 antibody) in primary central nervous system lymphoma: a phase 2 study” on Signal Transduct Target Ther, which presented the efficacy and safety of PD-1 antibody sintilimab combined with HD-MTX, temozolomide, and rituximab (SMTR) from a single-arm phase 2 trial in patients with PCNSL as a first-line treatment.
• On December 8, 2023, tricision won the 8th "Maker China" Beijing SMEs Innovation and Entrepreneurship Competition and "Maker Beijing 2023" Innovation and Entrepreneurship Competition Special Award.

2024

• On January 30, 2024, the LNP core key technology independently developed by tricision- "lipid compounds and their application in nucleic acid delivery" was granted a patent.